Literature DB >> 6941392

Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis. An endoscopic assessment.

A D Morris, S D Holt, G R Silvoso, J Hewitt, W Tatum, J Grandione, J H Butt, K J Ivey.   

Abstract

A prospective endoscopic study was carried out in 65 patients with rheumatoid arthritis to assess the prevalence of gastroduodenal lesions on aspirin alone or aspirin plus another anti-inflammatory drug (n = 26). All patients were taking greater than or equal to 8 tablets aspirin/day for greater than or equal to 3 months. Drug therapy consisted of regular, buffered or enteric-coated aspirin +/- one other non-steroidal anti-inflammatory drug or less than or equal to 10 mg prednisone/day. Endoscopic findings were graded as normal, or gastric and/or duodenal erythema, erosions, or ulcer; only the most serious lesion was tabulated. Fifty-three percent of patients on aspirin alone has a gastric ulcer or erosions, and 13% duodenal ulcer or erosions compared to 35% with gastric lesions and 4% with duodenal lesions on aspirin plus a second drug. Twenty-two percent of patients taking regular aspirin had gastric ulcers compared to only 6% taking enteric coated. Patients on enteric coated aspirin and prednisone had only a 10% prevalence of severe gastro-duodenal lesions. In conclusion, the combination of a second anti-inflammatory drug and aspirin therapy did not result in a higher prevalence of gastro-duodenal damage over that produced by aspirin therapy alone. Enteric coated aspirin produced significantly fewer serious lesions than regular or buffered aspirin. The combination of enteric-coated aspirin plus low dose prednisone caused a low prevalence of severe gastro-duodenal lesions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6941392

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

Review 1.  NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus.

Authors:  G D Champion; P H Feng; T Azuma; D E Caughey; K H Chan; S Kashiwazaki; H C Liu; A R Nasution; M Nobunaga; S Prichanond; T P Torralba; V Udom; D Utis; S R Wang; W S Wong; D J Yang; M C Yoo
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin.

Authors:  R Jaszewski; R Calzada; R Dhar
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

Review 3.  Gastrointestinal mucosal lesions. A drug formulation problem.

Authors:  O Brors
Journal:  Med Toxicol       Date:  1987 Mar-Apr

4.  Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day.

Authors:  F L Lanza; M F Rack; G S Wagner; T K Balm
Journal:  Dig Dis Sci       Date:  1985-06       Impact factor: 3.199

5.  Interobserver variation in assessment of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs.

Authors:  N Hudson; S Everitt; C J Hawkey
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

6.  The shape/morphology balance: a study of stealth liposomes via fractal analysis and drug encapsulation.

Authors:  Natassa Pippa; Faidra Psarommati; Stergios Pispas; Costas Demetzos
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

7.  Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs.

Authors:  R Knill-Jones; M Drummond; H Kohli; L Davies
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

8.  Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs.

Authors:  M G Robinson; J W Griffin; J Bowers; F J Kogan; D G Kogut; F L Lanza; C W Warner
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.